
CLAIMS

1. A compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, having the structural formula (I), shown below:



(I)

wherein

R^2 is hydrogen, halo, cyano, hydroxy, (1-6C)alkyl, (1-6C)alkoxy or (1-6C)haloalkyl;

R^3 is hydrogen, halo, cyano, hydroxy, (1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy, amino-(1-6C)alkyl or (1-6C)haloalkyl;

R^4 is hydrogen, halo, cyano, hydroxy, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)haloalkyl, (1-6C)haloalkoxy or $NR^{4A}R^{4B}$, wherein R^{4A} and R^{4B} are each independently selected from hydrogen or (1-6C)alkyl;

R^5 is hydrogen, halo, cyano, hydroxy, (1-6C)alkyl, (1-6C)alkoxy or (1-6C)haloalkyl; or

R^4 and R^5 are linked such that, together with the atoms to which they are attached, they form a 4-6 membered heterocyclyl or a heteroaryl, wherein any 4-6 membered heterocyclyl or heteroaryl is optionally substituted by one or more R^A, wherein each R^A is independently selected from halo, cyano, hydroxy, oxo, (1-6C)alkyl, (1-6C)alkoxy or (1-6C)haloalkyl;

X is N, CH or CR^6, wherein R^6 is halo, cyano, (1-6C)alkyl or (1-6C)haloalkyl;

Y^1 is $-CH_2-$, C(=O)- or $-CHR^B$, wherein R^B is selected from halo, cyano, methyl, methoxy, CF_3, $-OCF_3$ or hydroxymethyl;

Y^2 is $-CH_2-$, -C(=O)-, $-CHR^C-$, $-CH_2-CH_2-$, $-CH_2-CHR^C-$ or $-CHR^C-CH_2-$, wherein R^C is selected from halo, cyano, methyl, methoxy, CF_3, $-OCF_3$ or hydroxymethyl;

A^1 is selected from N, CH, CR^7 or CR^{12};

A^2 is selected from N, CH, CR^7 or CR^{12};

A^3 is selected from N, CH or CR^{13};


A^4 is selected from N, CH or CR^{14};

with the proviso that:

only one or two of A^1, A^2, A^3 or A^4 can be N; and

one of A^1 and A^2 is CR^7;

R^7 is a group of the formula (IA) or (IB) shown below:



(IA) (IB)

wherein ~~~ denotes the point of attachment to A_1 or A_2,


R^{8A} is hydrogen, (1-6C)alkyl, hydroxy-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-(1-4C)alkyl, aryl-(1-4C)alkyl, heterocyclyl-(1-4C)alkyl, heteroaryl-(1-4C)alkyl or 8- to 12-membered carbocyclyl,

wherein any alkyl moiety present in R^{8A} is optionally substituted by one or more substituents independently selected from halo, hydroxy, cyano, oxo, (1-6C)alkoxy, (3-6C)cycloalkoxy, phenyl or 4- to 6-membered heterocyclyl; and wherein any phenyl or 4- to 6-membered heterocyclyl is optionally further substituted by one or more substituents independently selected from halo, hydroxy, cyano, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl or (3-6C)cycloalkoxy; and

wherein any alkoxy, cycloalkyl, aryl, heterocyclyl, heteroaryl or carbocyclyl moiety present in R^{8A} is optionally substituted by one or more substituents independently selected from halo, hydroxy, cyano, oxo, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)haloalkyl, (3-6C)cycloalkoxy, phenyl or 4- to 6-membered heterocyclyl; and

wherein any phenyl or 4- to 6-membered heterocyclyl is optionally further substituted by one or more substituents independently selected from halo, hydroxy, cyano, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl or (3-6C)cycloalkoxy;

R^8 is a group of the formula (IA-I) or (IA-II) shown below:



(IA-I) (IA-II)

wherein ~~~ denotes the point of attachment,

R^{8B} and R^{8D} are each independently selected from the group consisting of hydrogen, halo, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl and $-C(O)NR^{8F}R^{8G}$, wherein R^{8F} and R^{8G} are each independently selected from hydrogen or (1-4C)alkyl;

wherein any alkyl moiety present in R^{8B} and/or R^{8D} is optionally substituted with one or more substituents independently selected from halo, hydroxy, cyano, oxo, (1-6C)alkoxy, (3-6C)cycloalkoxy, phenyl or 4- to 6-membered heterocyclyl; and

wherein any cycloalkyl moiety present in R^{8B} and/or R^{8D} is optionally substituted with one or more substituents independently selected from halo, hydroxy, cyano, oxo, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)haloalkyl, (3-6C)cycloalkoxy, phenyl or 4- to 6-membered heterocyclyl;

R^{8C} is selected from hydrogen, halo, (1-6C)alkyl, (1-6C)alkoxy, [(1-4C)alkyl]amino, di-[(1-4C)alkyl]amino, amino-(1-4C)alkyl, [(1-4C)alkyl]amino-(1-4C)alkyl, di-[(1-4C)alkyl]amino-(1-4C)alkyl, [(1-4C)alkyl][(3-6C)cycloalkyl]amino-(1-4C)alkyl, di[(3-6C)cycloalkyl]amino-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl, cycloalkyl-(1-4C)alkyl, aryl-(1-4C)alkyl, heterocyclyl-(1-4C)alkyl or heteroaryl-(1-4C)alkyl;

wherein any alkyl moiety present in R^{8C} is optionally substituted with one or more substituents independently selected from halo, hydroxy, cyano, oxo, (1-6C)alkoxy, $NR^{8CA}R^{8CB}$ (wherein R^{8CA} and R^{8CB} are each independently selected from

hydrogen and (1-6C)alkyl), (3-6C)cycloalkoxy, phenyl or 4- to 6-membered heterocyclyl; and wherein any phenyl or 4- to 6-membered heterocyclyl is optionally further substituted by one or more substituents independently selected from halo, hydroxy, cyano, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl or (3-6C)cycloalkoxy; and

wherein any alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl moiety present in R^{8C} is optionally substituted with one or more substituents independently selected from halo, hydroxy, cyano, oxo, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)haloalkyl, $NR^{8CC}R^{8CD}$ (wherein R^{8CC} and R^{8CD} are each independently selected from hydrogen and (1-6C)alkyl), (3-6C)cycloalkoxy, phenyl or 4- to 6-membered heterocyclyl; and wherein any phenyl or 4- to 6-membered heterocyclyl is optionally further substituted by one or more substituents independently selected from halo, hydroxy, cyano, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl or (3-6C)cycloalkoxy;

or R^{8A} and R^{8D} are linked such that, together with the atoms to which they are attached, they form a 4-6 membered heterocyclyl, wherein any 4-6 membered heterocyclyl is optionally substituted by one or more substituents independently selected from halo, hydroxy, cyano, oxo, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)haloalkyl, (3-6C)cycloalkoxy, phenyl or 4- to 6-membered heterocyclyl;

R^{8E} is selected from the group consisting of hydrogen, halo, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl,

wherein any alkyl moiety present in R^{8E} is optionally substituted with one or more substituents independently selected from halo, hydroxy, cyano, oxo, (1-6C)alkoxy, (3-6C)cycloalkoxy, phenyl or 4- to 6-membered heterocyclyl; and

wherein any cycloalkyl moiety present in R^{8E} is optionally substituted with one or more substituents independently selected from halo, hydroxy, cyano, oxo, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)haloalkyl, (3-6C)cycloalkoxy, phenyl or 4- to 6-membered heterocyclyl;

R^{12} is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, (3-6C)cycloalkyl, wherein any (1-2C)alkyl, (1-2C)alkoxy or (3-6C)cycloalkyl is optionally substituted by one or more halo or (1-2C)alkoxy, or

R^{12} is $-(CHR_p)_f-Z^{12}$,

wherein R_p is hydrogen or methyl;

f is 0 or 1; and

Z^{12} is $-OR^{20}$, $-NR^{21}R^{22}$, $-C(O)NR^{21}R^{22}$ or $-NR^{23}C(O)R^{24}$;

wherein R^{20} is (1-4C)alkyl, (3-7C)cycloalkyl, phenyl, a carbon-linked 4 to 6-membered heterocyclyl, a 5 or 6 membered heteroaryl, $-(CHR_q)_e$-(3-7C)cycloalkyl, $-(CHR_q)_e$-phenyl, $-(CHR_q)_e$-[4 to 6-membered heterocyclyl] or $-(CHR_q)_e$-[5 or 6 membered heteroaryl],

wherein R_q is hydrogen or methyl; and

e is 0 or 1;

R^{21} and R^{22} are each independently selected from hydrogen, (1-6C)alkyl, (2-6C)alkanoyl, (3-7C)cycloalkyl, phenyl, a carbon-linked 4 to 6-membered heterocyclyl, a 5 or 6 membered heteroaryl, $-(CHR_r)_d$-(3-7C)cycloalkyl, $-(CHR_r)_d$-phenyl, $-(CHR_r)_d$-[4 to 6-membered heterocyclyl] or $-(CHR_r)_d$-[5 or 6 membered heteroaryl],

wherein R_r is hydrogen or methyl; and

d is 0 or 1;

or R^{21} and R^{22} are linked, such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclyl;

R^{23} is hydrogen or (1-2C)alkyl;

R^{24} is (1-6C)alkyl, (2-6C)alkynyl, (3-7C)cycloalkyl, phenyl, a carbon-linked 4 to 6-membered heterocyclyl, a 5 or 6 membered heteroaryl, $-(CHR_s)_c$-(3-7C)cycloalkyl, $-(CHR_s)_c$-phenyl, $-(CHR_s)_c$-[4 to 6-membered heterocyclyl] or $-(CHR_s)_c$-[5 or 6 membered heteroaryl],

wherein R_s is hydrogen or methyl; and

c is 0 or 1;

wherein each of R^{20}, R^{21}, R^{22}, R^{23} or R^{24} or any ring formed when R^{21} and R^{22} are linked, is optionally substituted with one or more R^D;

R^{13} is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy or (3-6C)cycloalkyl, wherein any (1-2C)alkyl, (1-2C)alkoxy or (3-6C)cycloalkyl is optionally substituted by one or more halo or (1-2C)alkoxy, or

R^{13} is $-(CHR_o)_h-Z^{13}$,

wherein R_o is hydrogen or methyl;

h is 0 or 1; and

Z^{13} is $-OR^{25}$, $-NR^{26}R^{27}$, $-C(O)NR^{26}R^{27}$ or $-NR^{28}C(O)R^{29}$;

wherein R^{25} is (1-4C)alkyl, (3-7C)cycloalkyl, phenyl, a carbon-linked 4 to 6-membered heterocyclyl, a 5 or 6 membered heteroaryl, $-(CHR_n)_i$-(3-7C)cycloalkyl, $-(CHR_n)_i$-phenyl, $-(CHR_n)_i$-[4 to 6-membered heterocyclyl] or $-(CHR_n)_i$-[5 or 6 membered heteroaryl],

wherein R_n is hydrogen or methyl; and

i is 0 or 1;

R^{26} and R^{27} are each independently selected from hydrogen, (1-6C)alkyl, (2-6C)alkanoyl, (3-7C)cycloalkyl, phenyl, a carbon-linked 4 to 6-membered heterocyclyl, a 5 or 6 membered heteroaryl, $-(CHR_m)_j$-(3-7C)cycloalkyl, $-(CHR_m)_j$-phenyl, $-(CHR_m)_j$-[4 to 6-membered heterocyclyl] or $-(CHR_m)_j$-[5 or 6 membered heteroaryl],

wherein R_m is hydrogen or methyl; and

j is 0 or 1;

or R^{26} and R^{27} are linked, such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclyl;

R^{28} is hydrogen or (1-2C)alkyl;

R^{29} is (1-6C)alkyl, (2-6C)alkynyl, (3-7C)cycloalkyl, phenyl, a carbon-linked 4 to 6-membered heterocyclyl, a 5 or 6 membered heteroaryl, $-(CHR_l)_k$-(3-7C)cycloalkyl, $-(CHR_l)_k$-phenyl, $-(CHR_l)_k$-[4 to 6-membered heterocyclyl] or $-(CHR_l)_k$-[5 or 6 membered heteroaryl],

wherein R_l is hydrogen or methyl; and

k is 0 or 1;

wherein each of R^{25}, R^{26}, R^{27}, R^{28} or R^{29} or any ring formed when R^{26} and R^{27} are linked, is optionally substituted with one or more R^D;

R^{14} is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy or (3-6C)cycloalkyl, wherein any (1-2C)alkyl, (1-2C)alkoxy or (3-6C)cycloalkyl is optionally substituted by one or more halo or (1-2C)alkoxy, or

R^{14} is $-(CHR_k)_m-Z^{14}$,

wherein R_k is hydrogen or methyl;

m is 0 or 1; and

Z^{14} is $-OR^{30}$, $-NR^{31}R^{32}$, $-C(O)NR^{31}R^{32}$ or $-NR^{33}C(O)R^{34}$;

wherein R^{30} is (1-4C)alkyl, (3-7C)cycloalkyl, a carbon-linked 4 to 6-membered heterocyclyl, a 5 or 6 membered heteroaryl, $-(CHR_j)_o$-(3-7C)cycloalkyl, $-(CHR_j)_o$-[4 to 6-membered heterocyclyl] or $-(CHR_j)_o$-[5 or 6 membered heteroaryl],

wherein R_j is hydrogen or methyl; and

o is 0 or 1;

R^{31} and R^{32} are each independently selected from hydrogen, (1-6C)alkyl, (2-6C)alkanoyl, (3-7C)cycloalkyl, a carbon-linked 4 to 6-membered heterocyclyl, a 5 or 6 membered heteroaryl, $-(CHR_i)_p$-(3-7C)cycloalkyl, $-(CHR_i)_p$-[4 to 6-membered heterocyclyl] or $-(CHR_i)_p$-[5 or 6 membered heteroaryl],

wherein R_i is hydrogen or methyl; and

p is 0 or 1;

or R^{31} and R^{32} are linked, such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring;

R^{33} is hydrogen or (1-2C)alkyl;

R^{34} is (1-6C)alkyl, (2-6C)alkynyl, (3-7C)cycloalkyl, a carbon-linked 4 to 6-membered heterocyclyl, a 5 or 6 membered heteroaryl, $-(CHR_h)_q$-(3-

7C)cycloalkyl, -(CHR_h)$_q$-[4 to 6-membered heterocyclyl] or -(CHR_h)$_q$-[5 or 6 membered heteroaryl],

wherein R_h is hydrogen or methyl; and

q is 0 or 1;

wherein each of R^{30}, R^{31}, R^{32}, R^{33} or R^{34}, or any ring formed when R^{31} and R^{32} are linked, is optionally substituted with one or more R^D;

and wherein each R^D is independently selected from the group consisting of oxo, halo, cyano, hydroxy, (1-4C)alkyl, or a group:

$$-L^1-X^1-Q^1$$

wherein:

L^1 is absent or (1-2C)alkylene;

X^1 is absent or is selected from the group consisting of -O-, -C(O)-, -C(O)-O-, -O-C(O)-, -$S(O)_{0-2}$-, -C(O)-N(R^{15})-, -N(R^{15})-C(O)-, -NR^{15}-, -N(R^{15})-C(O)-NR^{15}-, -SO_2N(R^{15})-, or -N(R^{15})SO_2-, where each R^{15} is independently selected from hydrogen or (1-4C)alkyl; and

Q^1 is selected from the group consisting of hydrogen, (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, or (3-6C)cycloalkyl.

2. A compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, according to claim 1, wherein any one or both of the following statements (A)-(B) applies:

(A) R^2 is hydrogen, halo, hydroxy, (1-4C)alkyl, (1-4C)alkoxy or (1-4C)haloalkyl;

(B) R^3 is hydrogen or methyl.

3. A compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, according to claim 1 or 2, wherein any one or both of the following statements (A)-(B) applies:

(A) R^4 is hydrogen, halo, hydroxy, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy or $NR^{4A}R^{4B}$, wherein R^{4A} and R^{4B} are each independently selected from hydrogen or (1-4C)alkyl;

(B) R^5 is hydrogen, fluoro, chloro, bromo, cyano, methyl, ethyl, propyl (e.g., n-propyl or i-propyl), butyl (e.g., n-butyl, i-butyl or t-butyl), methoxy or CF_3.

4. A compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, according to claim 1 or 2, wherein R^4 and R^5 are linked such that, together with the atoms to which they are attached, they form a 5-membered heterocyclyl comprising 1 or 2 nitrogen atoms or a 5-membered heteroaryl comprising 1 or 2 nitrogen atoms, wherein any 5-membered heterocyclyl or 5-membered heteroaryl is optionally substituted by one, two or three R^A.

5. A compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, according to any one of the preceding claims, wherein any one or both of the following statements (A)-(B) applies:

(A) each R^A is independently selected from fluoro, chloro, hydroxy, oxo, methyl or ethyl;

(B) X is N, CH, C-Cl, C-F, C-Br, C-CN, C-CH_3, C-CH_2CH_3, C-CH_2F, C-CHF_2 or C-CF_3.

6. A compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, according to any one of the preceding claims, wherein any one or both of the following statements (A)-(B) applies:

(A) Y^1 is -CH_2- and/or Y^2 is -CH_2- or -CH_2-CH_2-;

(B) A^1 is selected from N, CH, CR^7 or CR^{12};

A^2 is selected from N, CH, CR^7 or CR^{12};

A^3 is selected from N, CH or CR^{13};

A^4 is selected from N, CH or CR^{14};

with the proviso that:

only one of A^1, A^2, A^3 or A^4 can be N;

one of A^1 and A^2 is CR^7;

A^3 cannot be CR^{13} when A^4 is CR^{14}; and

A^4 cannot be CR^{14} when A^3 is CR^{13}.

7. A compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, according to any one of the preceding claims, wherein any one or both of the following statements (A)-(B) applies:

(A) R^{8A} is hydrogen, (1-4C)alkyl, hydroxy-(1-2C)alkyl, (1-2C)alkoxy-(1-2C)alkyl, 4- to 6-membered cycloalkyl, aryl, 4- to 6-membered heterocyclyl, heteroaryl, 4- to 6-membered cycloalkyl-(1-2C)alkyl, aryl-(1-2C)alkyl, 4- to 6-membered heterocyclyl-(1-2C)alkyl, heteroaryl-(1-2C)alkyl or 8- to 10-membered carbocyclyl,

wherein any alkyl moiety present in R^{8A} is optionally substituted by one or more substituents independently selected from halo, hydroxy, cyano, oxo, (1-3C)alkoxy, (4-6C)cycloalkoxy, phenyl or 5- to 6-membered heterocyclyl;

wherein any alkoxy, cycloalkyl, aryl, heterocyclyl, heteroaryl or carbocyclyl moiety present in R^{8A} is optionally substituted by one or more substituents independently selected from halo, hydroxy, cyano, oxo, (1-3C)alkyl, (1-3C)alkoxy, (1-3C)haloalkyl, (4-6C)cycloalkoxy, phenyl or 5- to 6-membered heterocyclyl;

(B) R^{8A} is hydrogen, methyl, ethyl, propyl (e.g., i-propyl or n-propyl), hydroxyethyl, methoxyethane, phenyl, piperidine, pyrrolidine, phenyl-(1-2C)alkyl, pyrrolidine-(1-2C)alkyl, pyrazole-(1-2C)alkyl, pyridine-(1-2C)alkyl, morpholine-(1-2C)alkyl, tetrahydropyran-(1-2C)alkyl, or dihydroindene,

wherein any alkyl moiety present in R^{8A} is optionally substituted by one substituent selected from chloro, fluoro, hydroxy, methoxy or phenyl;

wherein any alkoxy, cycloalkyl, aryl, heterocyclyl, heteroaryl or carbocyclyl moiety present in R^{8A} is optionally substituted by one substituent selected from chloro, fluoro, hydroxy, methyl, methoxy or phenyl.

8. A compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, according to any one of the preceding claims, wherein R^{8B} and R^{8D} are each independently selected from the group consisting of hydrogen, fluoro, chloro or methyl.

9. A compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, according to any one of the preceding claims, wherein any one or more of the following statements (A)-(C) applies:

(A) R^{8C} is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, [(1-4C)alkyl]amino, di-[(1-4C)alkyl]amino, amino-(1-4C)alkyl, [(1-4C)alkyl]amino-(1-4C)alkyl, di-[(1-4C)alkyl]amino-(1-4C)alkyl, [(1-4C)alkyl][(3-6C)cycloalkyl]amino-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl, 4- to 6-membered cycloalkyl-(1-4C)alkyl, aryl-(1-4C)alkyl, 4- to 6-membered heterocyclyl-(1-4C)alkyl or heteroaryl-(1-4C)alkyl,

wherein any alkyl moiety present in R^{8C} is optionally substituted with one or more substituents independently selected from halo, hydroxy, cyano, oxo, (1-3C)alkoxy, $NR^{8CA}R^{8CB}$ (wherein R^{8CA} and R^{8CB} are each independently selected from hydrogen and (1-3C)alkyl), (4-6C)cycloalkoxy, phenyl or 5- to 6-membered heterocyclyl; and wherein any phenyl or 5- to 6-membered heterocyclyl is optionally further substituted by one or more substituents independently selected from halo, hydroxy, cyano, (1-2C)alkyl, (1-2C)alkoxy, (4-6C)cycloalkyl or (4-6C)cycloalkoxy; and

wherein any alkoxy, cycloalkyl, aryl, heterocyclyl or heteroaryl moiety present in R^{8C} is optionally substituted with one or more substituents independently selected from halo, hydroxy, cyano, oxo, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)haloalkyl, $NR^{8CC}R^{8CD}$ (wherein R^{8CC} and R^{8CD} are each independently selected from hydrogen and (1-4C)alkyl), (4-6C)cycloalkoxy, phenyl or 5- to 6-membered heterocyclyl; and wherein any phenyl or 5- to 6-membered heterocyclyl is optionally further substituted by one or more substituents independently selected from halo, hydroxy, cyano, (1-2C)alkyl, (1-2C)alkoxy, (4-6C)cycloalkyl or (4-6C)cycloalkoxy;

(B) R^{8C} is selected from hydrogen, methyl, $-CH_2-NR^{8C1}R^{8C2}$, $-CH_2-N(R^{8C1})$(3C)cycloalkyl, $NR^{8C1}R^{8C2}$, (1-2C)alkoxy-(1-2C)alkyl, 4- to 6-membered nitrogen-containing heterocyclyl-(1-2C)alkyl or nitrogen-containing heteroaryl-(1-2C)alkyl, wherein R^{8C1} and R^{8C2} are each independently selected from hydrogen, methyl and ethyl,

wherein any alkyl moiety present in R^{8C} is optionally substituted with one or two substituents independently selected from fluoro, chloro, hydroxy, methoxy or NH_2; and

wherein any alkoxy, heterocyclyl or heteroaryl moiety present in R^{8C} is optionally substituted with one or two substituents independently selected from fluoro, chloro, hydroxy, methyl, methoxy or NH_2;

(C) R^{8c} is selected from hydrogen, methyl, $-CH_2-NH_2$, $-CH_2-NMe_2$, $-CH_2-NEt_2$, $-CH_2-N(Me)Et$, $CH_2-N(Me)$cyclopropyl, $-NH_2$, $-NMe_2$, (1-2C)alkoxy-(1-2C)alkyl, pyrrolidine-(1-2C)alkyl, morpholine-(1-2C)alkyl or azetidine-(1-2C)alkyl,

wherein any alkoxy, heterocyclyl or heteroaryl moiety present in R^{8C} is optionally substituted with two substituents independently selected from fluoro, chloro, hydroxy or methyl.

10. A compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, according to any one of the preceding claims, wherein R^{8A} and R^{8D} are linked such that, together with the atoms to which they are attached, they form a 5-membered heterocyclyl,

wherein any 5-membered heterocyclyl is optionally substituted by one or two substituents independently selected from fluoro, chloro, hydroxy, methyl, methoxy, CHF_2 or CF_3.

11. A compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, according to any one of the preceding claims, wherein any one or more of the following statements (A)-(C) applies:

(A) R^{12} is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy or (3-6C)cycloalkyl, wherein any (1-2C)alkyl, (1-2C)alkoxy or (3-6C)cycloalkyl is optionally substituted by one or more halo or (1-2C)alkoxy, or

R^{12} is $-(CHR_p)_f-Z^{12}$,

wherein R_p is hydrogen or methyl;

f is 0 or 1; and

Z^{12} is $-OR^{20}$ or $-NR^{21}R^{22}$;

wherein R^{20} is (1-3C)alkyl, (3-6C)cycloalkyl, phenyl, a carbon-linked 4 to 6-membered heterocyclyl or a 5 or 6 membered heteroaryl,

R^{21} and R^{22} are each independently selected from hydrogen, (1-2C)alkyl, (2-3C)alkanoyl, (4-6C)cycloalkyl, phenyl, a carbon-linked 4 to 6-membered heterocyclyl or a 5 or 6 membered heteroaryl;

or R^{21} and R^{22} are linked, such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclyl;

wherein each of R^{20}, R^{21} or R^{22} or any ring formed when R^{21} and R^{22} are linked, is optionally substituted with one or two R^D;

(B) R^{13} is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy or (3-6C)cycloalkyl, wherein any (1-2C)alkyl, (1-2C)alkoxy or (3-6C)cycloalkyl is optionally substituted by one or more halo or (1-2C)alkoxy, or

R^{13} is $-(CHR_o)_h-Z^{13}$,

wherein R_o is hydrogen or methyl;

h is 0 or 1; and

Z^{13} is $-OR^{25}$ or $-NR^{26}R^{27}$;

wherein R^{25} is (1-3C)alkyl, (3-6C)cycloalkyl, phenyl, a carbon-linked 4 to 6-membered heterocyclyl or a 5 or 6 membered heteroaryl,

R^{26} and R^{27} are each independently selected from hydrogen, (1-2C)alkyl, (2-3C)alkanoyl, (4-6C)cycloalkyl, phenyl, a carbon-linked 4 to 6-membered heterocyclyl or a 5 or 6 membered heteroaryl,

or R^{26} and R^{27} are linked, such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclyl;

wherein each of R^{25}, R^{26} or R^{27} or any ring formed when R^{26} and R^{27} are linked, is optionally substituted with one or two R^D;

(C) R^{14} is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy or (3-6C)cycloalkyl, wherein any (1-2C)alkyl, (1-2C)alkoxy or (3-6C)cycloalkyl is optionally substituted by one or more halo or (1-2C)alkoxy, or

R^{14} is $-(CHR_k)_m-Z^{14}$,

wherein R_k is hydrogen or methyl;

m is 0 or 1; and

Z^{14} is $-OR^{30}$ or $-NR^{31}R^{32}$;

wherein R^{30} is (1-3C)alkyl, (3-6C)cycloalkyl, a carbon-linked 4 to 6-membered heterocyclyl or a 5 or 6 membered heteroaryl,

R^{31} and R^{32} are each independently selected from hydrogen, (1-2C)alkyl, (2-3C)alkanoyl, (3-6C)cycloalkyl, a carbon-linked 4 to 6-membered heterocyclyl or a 5 or 6 membered heteroaryl,

or R^{31} and R^{32} are linked, such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring;

wherein each of R^{30}, R^{31} or R^{32}, or any ring formed when R^{31} and R^{32} are linked, is optionally substituted with one or two R^D.

12. A compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, according to any one of the preceding claims, wherein each R^D is independently selected from the group consisting of oxo, chloro, fluoro, cyano, hydroxy, methyl, or a group:

$$-L^1-X^1-Q^1$$

wherein:

L^1 is absent or methylene;

X^1 is absent or is selected from the group consisting of -O-, -C(O)-, -C(O)-O-, -NH- or NMe-; and

Q^1 is selected from the group consisting of hydrogen, (1-2C)alkyl, (2-3C)alkenyl, (2-3C)alkynyl, or (3-6C)cycloalkyl.

13. A compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, according to any one of the preceding claims, wherein the compound is selected from any one of the following:

(E)-N-(2-(3-Chloro-4,6-dihydroxy-2-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-Benzyl-N-(2-(2,4-dihydroxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide;

(E)-N-Benzyl-N-(2-(2,4-dihydroxy-5-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide;

(E)-N-(2-(2,4-Dihydroxybenzoyl) isoindolin-4-yl)-4-(diethylamino)-N-((1-methyl-1H-pyrazol-4-yl)methyl)but-2-enamide;

(E)-4-(3,3-Difluoropyrrolidin-1-yl)-N-(2-(2,4-dihydroxy-5-methylbenzoyl)isoindolin-4-yl)but-2-enamide;

((E)-4-(3,3-Difluoroazetidin-1-yl)-N-(2-(2,4-dihydroxy-5-methylbenzoyl)isoindolin-4-yl)but-2-enamide;

N-(2-(2, 4-Dihydroxy-5-methylbenzoyl) isoindolin-4-yl) acrylamide;

(E)-N-(2-(2,4-Dihydroxy-6-methylbenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-(dimethylamino)but-2-enamide;

(E)-N-(2-(2,4-Dihydroxy-5-methylbenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-(dimethylamino)but-2-enamide;

(E)-N-(2-(2,4-Dihydroxy-5-methylbenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(2-(2,4-Dihydroxy-6-methylbenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(2-(2,4-Dihydroxy-5-isopropylbenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(2-(2,4-Dihydroxy-5-methylbenzoyl)isoindolin-4-yl)-4-(pyrrolidin-1-yl)but-2-enamide;

(E)-N-(2-(2, 4-Dihydroxy-5-methylbenzoyl) isoindolin-4-yl)-4-morpholinobut-2-enamide;

N-(2-(3-Chloro-4,6-dihydroxy-2-methylbenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-methylacrylamide;

N-(2-(5-Chloro-2,4-dihydroxybenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-methylacrylamide;

(E)-N-(2-(5-(tert-Butyl)-2-hydroxy-4-methoxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(2-(5-(tert-Butyl)-4-fluoro-2-hydroxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(2-(4,6-Dihydroxy-2,3-dimethylbenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

N-(2-(2,4-Dihydroxy-5-methylbenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-methylacrylamide;

N-Benzyl-N-(2-(2,4-dihydroxybenzoyl)isoindolin-4-yl)acrylamide;

N-Benzyl-N-(2-(2,4-dihydroxy-5-methylbenzoyl)isoindolin-4-yl)acrylamide;

(E)-N-(2-(2,4-Dihydroxybenzoyl) isoindolin-4-yl)-4-(dimethyl amino)-N-phenethylbut-2-enamide;

(E)-N-(2-(2-Chloro-4,6-dihydroxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(6-hydroxy-3,3-dimethylindoline-5-carbonyl)isoindolin-4-yl)-N-methylbut-2-enamide;

(E)-N-(2-(4,6-Dihydroxy-2,3-dimethylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(2-(5-(tert-Butyl)-2,4-dihydroxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(2-(2,4-Dihydroxy-5-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-ethylbut-2-enamide;

(E)-N-(2-(2,4-Dihydroxy-5-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-(2-hydroxyethyl)but-2-enamide;

(E)-N-(2-(2,4-Dihydroxy-5-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-(pyridin-4-ylmethyl)but-2-enamide;

(E)-N-(2-(2,4-Dihydroxy-5-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-(2-(pyridin-4-yl)ethyl)but-2-enamide;

(E)-N-(2-(2,4-Dihydroxy-5-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-(2-(pyridin-2-yl)ethyl)but-2-enamide;

(E)-N-(2-(2,4-Dihydroxy-5-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-(2-(pyridin-3-yl)ethyl)but-2-enamide;

(E)-N-(2-(4,6-Dihydroxy-2,3-dimethylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-(2-(pyridin-2-yl)ethyl)but-2-enamide;

E)-N-(2-(2,4-Dihydroxy-5-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-(2-(tetrahydro-2H-pyran-4-yl)ethyl)but-2-enamide;

(E)-N-(2-(2,4-Dihydroxy-5-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-(2-methoxyethyl)but-2-enamide;

(E)-N-(2-(2,4-Dihydroxy-5-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(2-(2,4-Dihydroxy-6-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(2-(5-Chloro-2,4-dihydroxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide;

(E)-N-(2-(2,4-Dihydroxy-5-methoxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide;

(E)-N-(2-(4,6-Dihydroxy-2,3-dimethylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(6-hydroxy-1H-indole-5-carbonyl)isoindolin-4-yl)but-2-enamide;

(E)-N-(2-(5-Bromo-2,4-dihydroxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide;

(E)-N-(2-(2,4-Dihydroxy-5-(trifluoromethyl)benzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(2-(5-Cyano-2,4-dihydroxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide;

(E)-N-(2-(2,4-Dihydroxy-6-(trifluoromethyl)benzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide;

(E)-N-(2-(2,4-Dihydroxy-5-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide;

(E)-N-(2-Benzoylisoindolin-4-yl)-4-(dimethylamino)but-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(4-hydroxy-2-methoxybenzoyl)isoindolin-4-yl)but-2-enamide;

(E)-N-(2-(2-(Difluoromethyl)-4-hydroxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide;

(E)-N-(2-(2-Chloro-4-hydroxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(6-hydroxy-1H-indazole-5-carbonyl)isoindolin-4-yl)but-2-enamide;

(E)-N-(2-(2,4-Dihydroxy-6-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide;

(E)-N-(2-(4-(Difluoromethyl)-2-hydroxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(5-fluoro-2,4-dihydroxybenzoyl)isoindolin-4-yl)but-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(6-hydroxybenzo[d]isoxazole-5-carbonyl)isoindolin-4-yl)but-2-enamide;

(E)-N-(2-(2,4-Dihydroxy-5-isopropylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide;

(E)-N-(2-(4-Amino-2-hydroxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(5-ethyl-2,4-dihydroxybenzoyl)isoindolin-4-yl)but-2-enamide;

(E)-N-(2-(2,4-Dihydroxy-5-isopropylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(2-(3-Chloro-4-(difluoromethoxy)-6-hydroxy-2-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(2-hydroxy-5-isopropylbenzoyl)isoindolin-4-yl)-N-methylbut-2-enamide;

(E)-N-(2-(5-(tert-Butyl)-2-hydroxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(2-(4-(Difluoromethoxy)-2-hydroxy-5-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(4-hydroxy-2,3-dimethylbenzoyl)isoindolin-4-yl)-N-methylbut-2-enamide;

(E)-N-(2-(3-(tert-Butyl)-4-hydroxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(4-hydroxy-3-methylbenzoyl)isoindolin-4-yl)-N-methylbut-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(4-hydroxy-3-isopropylbenzoyl)isoindolin-4-yl)-N-methylbut-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(4-hydroxy-3-isopropylbenzoyl)isoindolin-4-yl)but-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(4-hydroxy-3-(trifluoromethyl)benzoyl)isoindolin-4-yl)-N-methylbut-2-enamide;

(E)-N-(2-(3-Chloro-4-hydroxy-2-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

N-[2-(2,4-Dihydroxy-5-methyl-benzoyl)isoindolin-4-yl]-N-[2-(4-pyridyl)ethyl]prop-2-enamide;

N-(2-(2,4-Dihydroxy-5-methylbenzoyl)isoindolin-4-yl)-N-(2-(1-methylpyrrolidin-3-yl)ethyl)acrylamide;

N-(2-(2,4-Dihydroxy-5-methylbenzoyl)isoindolin-4-yl)-N-methylacrylamide;

N-(2-(5-(tert-Butyl)-2,4-dihydroxybenzoyl)isoindolin-4-yl)acrylamide;

N-(2-(5-(tert-Butyl)-2,4-dihydroxybenzoyl)isoindolin-4-yl)-N-methylacrylamide;

N-(2-(2,4-Dihydroxy-6-methylbenzoyl)isoindolin-4-yl)acrylamide;

(E)-N-[2-(2,4-Dihydroxy-5-methyl-benzoyl)isoindolin-4-yl]-4-(dimethylamino)-N-indan-2-yl-but-2-enamide;

N-(2-(2,4-Dihydroxy-5-methylbenzoyl)isoindolin-4-yl)-N-(2-morpholinoethyl)acrylamide;

N-(2-(2,4-Dihydroxy-6-methylbenzoyl)isoindolin-4-yl)-N-methylacrylamide;

(E)-N-[2-(2,4-Dihydroxybenzoyl)isoindolin-4-yl]-4-(dimethylamino)but-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(2-hydroxy-4-methoxybenzoyl)isoindolin-4-yl)but-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(2-hydroxy-5-methylbenzoyl)isoindolin-4-yl)but-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(4-hydroxy-3-methylbenzoyl)isoindolin-4-yl)but-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(2-fluoro-4-hydroxybenzoyl)isoindolin-4-yl)but-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(4-hydroxy-2-methylbenzoyl)isoindolin-4-yl)but-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(5-hydroxypicolinoyl)isoindolin-4-yl)but-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(2-methoxybenzoyl)isoindolin-4-yl)but-2-enamide;

(E)-N-(2-(2,4-Dihydroxy-5-(trifluoromethyl)benzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide;

(E)-N-(2-(5-(tert-Butyl)-2,4-dihydroxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide;

(E)-N-(2-(2,4-Dihydroxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide;

(E)-N-(2-(2,4-Dihydroxy-5-methylbenzoyl)isoindolin-4-yl)-4-methoxybut-2-enamide;

1-(2-(2,4-Dihydroxy-5-methylbenzoyl)isoindolin-4-yl)-3-(2-(dimethylamino)ethylidene)pyrrolidin-2-one;

N-(2-(2,4-Dihydroxy-5-methylbenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-(1-methylpiperidin-4-yl)acrylamide;

(E)-N-(2-(4,6-Dihydroxy-2,3-dimethylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-ethylbut-2-enamide;

N-(2-(4,6-Dihydroxy-2,3-dimethylbenzoyl)isoindolin-4-yl)-N-(2-methoxyethyl)acrylamide;

N-(2-(4,6-Dihydroxy-2,3-dimethylbenzoyl)isoindolin-4-yl)-N-methylacrylamide;

(E)-N-(2-(5-(tert-Butyl)-2,4-dihydroxybenzoyl)-5-chloroisoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(5-Chloro-2-(2, 4-dihydroxy-5-methylbenzoyl)isoindolin-4-yl)-4-(dimethyl amino)-N-methylbut-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(6-hydroxy-3,3-dimethyl-2-oxoindoline-5-carbonyl)isoindolin-4-yl)-N-methylbut-2-enamide;

(E)-N-(2-(3-Chloro-4,6-dihydroxy-2-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-ethylbut-2-enamide;

(E)-N-(2-(3-Chloro-4,6-dihydroxy-2-methylbenzoyl)isoindolin-4-yl)-4-(ethyl(methyl)amino)-N-methylbut-2-enamide;

(E)-N-(7-Chloro-2-(2,4-dihydroxy-5-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(7-Chloro-2-(4,6-dihydroxy-2,3-dimethylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

N-(2-(3-Chloro-4,6-dihydroxy-2-methylbenzoyl)isoindolin-4-yl)-N-methyl acrylamide;

(E)-N-(5-Chloro-2-(4,6-dihydroxy-2,3-dimethylbenzoyl) isoindolin-4-yl)-4-(dimethyl amino)-N-methylbut-2-enamide;

(E)-N-(2-(3-Chloro-2-fluoro-4,6-dihydroxybenzoyl) isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(2-(3-Chloro-2-fluoro-4,6-dihydroxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-ethylbut-2-enamide;

N-(2-(3-Chloro-4,6-dihydroxy-2-methylbenzoyl) isoindolin-4-yl)-N-ethyl acrylamide;

N-(2-(3-Chloro-2-fluoro-4,6-dihydroxybenzoyl) isoindolin-4-yl)-N-methylacrylamide;

N-(2-(2,4-Dihydroxy-5-methylbenzoyl)-6-(2-(dimethylamino) ethoxy) isoindolin-4-yl)-N-methylacrylamide;

(E)-4-(Dimethylamino)-N-(2-(6-hydroxy-2,3-dimethyl-1H-indole-5-carbonyl) isoindolin-4-yl)-N-methylbut-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(6-hydroxy-2-methyl-1H-indole-5-carbonyl) isoindolin-4-yl)-N-methylbut-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(6-hydroxy-3-methyl-1H-indole-5-carbonyl) isoindolin-4-yl)-N-methylbut-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(4-fluoro-2-hydroxy-5-isopropylbenzoyl) isoindolin-4-yl)-N-methylbut-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(2-hydroxy-4-methoxy-5-methylbenzoyl)isoindolin-4-yl)-N-methylbut-2-enamide;

(E)-N-(2-(3-(tert-Butyl)-2-fluoro-6-hydroxy-5-(hydroxymethyl)benzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

N-(2-(3-(Aminomethyl)-5-(tert-butyl)-6-fluoro-2-hydroxybenzoyl)isoindolin-4-yl)-N-methylacrylamide;

(E)-N-(2-(5-(tert-Butyl)-2-hydroxy-4-methoxybenzoyl)-5-chloroisoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(2-hydroxy-5-isopropyl-4-methoxybenzoyl)isoindolin-4-yl)-N-methylbut-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(5-ethyl-2-hydroxy-4-methoxybenzoyl)isoindolin-4-yl)-N-methylbut-2-enamide;

(E)-N-(2-(3-Chloro-6-hydroxy-4-methoxy-2-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(2-(5-Chloro-2-hydroxy-4-methoxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

N-(2-(5-(tert-Butyl)-2-hydroxy-4-methoxybenzoyl)isoindolin-4-yl)-N-methylacrylamide;

N-(2-(5-Ethyl-2-hydroxy-4-methoxybenzoyl)isoindolin-4-yl)-N-methylacrylamide;

(E)-N-(2-(3-(tert-Butyl)-2-fluoro-6-hydroxybenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

N-(2-(3-(tert-Butyl)-2-fluoro-6-hydroxybenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-methylacrylamide;

N-(2-(3-Chloro-6-hydroxy-4-methoxy-2-methylbenzoyl)isoindolin-4-yl)-N-methylacrylamide;

N-(2-(5-Chloro-2-hydroxy-4-methoxybenzoyl) isoindolin-4-yl)-N-methyl acrylamide;

(E)-N-(2-(5-Chloro-2-hydroxy-4-methoxybenzoyl)-5-methylisoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(5-Chloro-2-(5-chloro-2-hydroxy-4-methoxybenzoyl) isoindolin-4-yl)-4-(dimethyl amino)-N-methylbut-2-enamide;

(E)-N-(5-Chloro-2-(2-hydroxy-5-isopropyl-4-methoxybenzoyl) isoindolin-4-yl)-4-(dimethyl amino)-N-methylbut-2-enamide;

(E)-N-(2-(5-(tert-Butyl)-2-hydroxy-4-methoxybenzoyl)-5-methylisoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

N-(2-(2-Hydroxy-5-isopropyl-4-methoxybenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-methylacrylamide;

N-(2-(4-Fluoro-2-hydroxy-5-isopropylbenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-methylacrylamide;

N-(2-(5-Chloro-2-hydroxy-4-methoxybenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-methylacrylamide;

N-(2-(2-Hydroxy-5-isopropyl-4-methoxybenzoyl)-6-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-methylacrylamide;

N-(2-(6-Hydroxy-3,3-dimethyl-2-oxoindoline-5-carbonyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-methylacrylamide;

N-(2-(6-Hydroxy-3,3-dimethyl-2-oxoindoline-5-carbonyl) isoindolin-4-yl)-N-methyl acrylamide;

N-(6-(2-Hydroxy-5-isopropyl-4-methoxybenzoyl)-5,6,7,8-tetrahydro-2,6-naphthyridin-3-yl)-N-methylacrylamide;

N-(7-(2-Hydroxy-5-isopropyl-4-methoxybenzoyl)-3-methyl-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)-N-methylacrylamide;

N-(6-(2-Hydroxy-5-isopropyl-4-methoxybenzoyl)-2-methyl-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-N-methylacrylamide;

(E)-N-(2-(3-Chloro-6-hydroxy-4-methoxy-2-methylbenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(2-hydroxy-5-isopropyl-4-methoxybenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-methylbut-2-enamide;

(E)-N-(2-(5-(tert-Butyl)-4-fluoro-2-hydroxybenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(4-fluoro-2-hydroxy-5-isopropylbenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-methylbut-2-enamide;

N-(2-(2-Hydroxy-5-isopropyl-4-methoxybenzoyl)isoindolin-4-yl)-N-methylacrylamide;

N-(6-(2-Hydroxy-5-isopropyl-4-methoxybenzoyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl) acrylamide;

(E)-N-(2-(3-Chloro-6-hydroxy-2-methylbenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(6-(5-(tert-Butyl)-2-hydroxybenzoyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(2-(5-(tert-Butyl)-2-hydroxybenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(5-Chloro-2-(4-hydroxy-3-isopropylbenzoyl) isoindolin-4-yl)-4-(dimethylamino) but-2-enamide;

(E)-N-(5-Chloro-2-(4-hydroxy-3-isopropylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

N-(2-(3-Chloro-6-hydroxy-4-methoxy-2-methylbenzoyl)-6-(2-(dimethylamino)ethoxy)-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-methylacrylamide;

N-(6-(2-(Dimethylamino)ethoxy)-2-(2-hydroxy-5-isopropyl-4-methoxybenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-methylbut-2-ynamide;

(E)-N-(5-Chloro-2-(3-chloro-6-hydroxy-4-methoxy-2-methylbenzoyl) isoindolin-4-yl)-4-(dimethyl amino)-N-methylbut-2-enamide;

(E)-N-(2-(5-(tert-Butyl)-2-fluoro-4-hydroxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(2-(5-(tert-Butyl)-2-hydroxy-4-methoxybenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

N-(2-(5-(tert-Butyl)-2-hydroxy-4-methoxybenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-methylacrylamide;

N-(2-(3-Chloro-2-fluoro-6-hydroxy-4-methoxybenzoyl)isoindolin-4-yl)-N-methylacrylamide;

N-(5-Chloro-2-(3-chloro-6-hydroxy-4-methoxy-2-methylbenzoyl) isoindolin-4-yl)-N-methyl acrylamide;

(E)-4-(Dimethylamino)-N-(2-(2-hydroxy-5-isopropyl-4-methoxybenzoyl)-5-methylisoindolin-4-yl)-N-methylbut-2-enamide;

N-(2-(4-Fluoro-2-hydroxy-5-isopropylbenzoyl)-6-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-methylacrylamide;

N-(6-Chloro-2-(2-hydroxy-5-isopropyl-4-methoxybenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-methylacrylamide;

N-(2-(2-Hydroxy-5-isopropyl-4-methoxybenzoyl)-8-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-methylacrylamide;

N-(6-(2-(Dimethylamino)ethoxy)-2-(2-hydroxy-5-isopropyl-4-methoxybenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-methylacrylamide;

N-(6-(3-Chloro-6-hydroxy-4-methoxy-2-methylbenzoyl)-5,6,7,8-tetrahydro-2,6-naphthyridin-3-yl)-N-methylacrylamide;

(E)-N-(7-(3-Chloro-6-hydroxy-4-methoxy-2-methylbenzoyl)-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)-N-methylbut-2-enamide;

N-(7-(3-Chloro-6-hydroxy-4-methoxy-2-methylbenzoyl)-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)-N-methylacrylamide;

N-(7-(3-Chloro-6-hydroxy-4-methoxy-2-methylbenzoyl)-3-methyl-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)-N-methylacrylamide;

N-(6-(3-Chloro-6-hydroxy-4-methoxy-2-methylbenzoyl)-2-methyl-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-N-methylacrylamide;

N-(2-(2-Hydroxy-5-isopropyl-4-methoxybenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-(1-methylpiperidin-4-yl) acrylamide;

(E)-N-(2-(4,6-dihydroxy-2,3-dimethylbenzoyl)-5-methylisoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(2-(4,6-Dihydroxy-2,3-dimethylbenzoyl)-6-methylisoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(6-(3-Chloro-6-hydroxy-4-methoxy-2-methylbenzoyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-N-methylbut-2-enamide;

N-(2-(3-Chloro-6-hydroxy-4-methoxy-2-methylbenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-methylacrylamide;

N-(2-(2-Hydroxy-5-isopropyl-4-methoxybenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-(1-methylpyrrolidin-3-yl)acrylamide;

((E)-N-(5-Chloro-2-(2-hydroxy-5-isopropyl-4-methoxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide;

(E)-N-(2-(3-Chloro-6-hydroxy-4-methoxy-2-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide;

N-(6-(3-Chloro-6-hydroxy-4-methoxy-2-methylbenzoyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)acrylamide;

(E)-N-(2-(3-Chloro-6-hydroxy-2-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

(E)-N-(7-Chloro-2-(3-chloro-6-hydroxy-4-methoxy-2-methylbenzoyl) isoindolin-4-yl)-4-(dimethylamino)-N-methylbut-2-enamide;

N-(7-Chloro-2-(3-chloro-6-hydroxy-4-methoxy-2-methylbenzoyl) isoindolin-4-yl)-N-methyl acrylamide;

(E)-4-(Dimethylamino)-N-(6-(2-hydroxy-5-isopropyl-4-methoxybenzoyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-N-methylbut-2-enamide;

N-(2-(3-Chloro-6-hydroxy-4-methoxy-2-methylbenzoyl)-6-(2-(dimethylamino)ethoxy)-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-methylbut-2-ynamide;

(E)-N-(5-Chloro-2-(3-chloro-4-hydroxy-2-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide;

(E)-N-(5-Chloro-2-(4-hydroxy-2,3-dimethylbenzoyl) isoindolin-4-yl)-4-(dimethylamino) but-2-enamide;

(*E*)-4-(Dimethylamino)-N-(2-(4-hydroxy-3-isopropylbenzoyl)-3-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-methylbut-2-enamide;

(E)-4-(Dimethylamino)-N-(2-(4-hydroxy-3-isopropylbenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-methylbut-2-enamide;

N-(2-(4-Hydroxy-3-isopropylbenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-(1-methylpiperidin-4-yl)acrylamide;

(E)-4-(Dimethylamino)-N-(6-(2-hydroxy-5-isopropyl-4-methoxybenzoyl)-2-methoxy-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-N-methylbut-2-enamide;

((E)-4-(Dimethylamino)-N-(6-(4-hydroxy-3-isopropylbenzoyl)-2-methoxy-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-N-methylbut-2-enamide;

(E)-N-(2-(3-Chloro-6-hydroxy-4-methoxy-2-methylbenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-N-methylbut-2-enamide;

N-(6-(3-Chloro-6-hydroxy-4-methoxy-2-methylbenzoyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)but-2-ynamide.

14. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined in any one of claims 1-13, in admixture with a pharmaceutically acceptable diluent or carrier.

15. A compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined in any one of claims 1-13, or a pharmaceutical composition as defined in claim 14:

(i) for use in therapy;

(ii) for use in the treatment of cancer;

(iii) for use in the treatment of cancer, wherein the compound or pharmaceutical composition is administered in combination with another anticancer agent (e.g., a chemotherapeutic agent, an immune checkpoint inhibitor, an immune stimulator or DNA damage repair modulator);

(iv) for use in the treatment of a triplet repeat disorder.